A federal judge ordered FDA to reconsider mifepristone restrictions
A Virginia federal judge ruled that FDA did not adequately justify special certification and paperwork rules for mifepristone, sending the 2023 restrictions back to the agency while other medication-abortion lawsuits continue. (sources: Guardian Us News Native, law.justia.com, stateline.org)
The federal judge ruled that the FDA's restrictions on mifepristone are arbitrary and capricious, declaring certain restrictions unlawful. The decision requires the FDA to reconsider its regulations regarding the drug.
- The judge found the FDA's restrictions on mifepristone to be arbitrary and capricious.
- The ruling affects the legality of certain restrictions on abortion medication.
- The decision may influence related pending legal cases.
Why it matters
The ruling could lead to changes in how mifepristone is regulated and accessed in the United States.
Connected public decisions
Follow the issue pages where this story connects to public action.
Contact officials
Act on Rules for medication abortion care
See the current decision, choose your position, and send a message through the issue page.
Take action on Rules for medication abortion careSources used · 3 sources